Clinical Trial Update: Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the effect of Tusamitamab Ravtansine on QTc interval in participants with metastatic solid tumors; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Tusamitamab Ravtansine (Tusamitamab Ravtansine)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm | Phase 1 | Status: TERMINATED